Design, development and permeation studies of nebivolol hydrochloride from novel matrix type transdermal patches

Authors
Vijay Singh Jatav 1
Jitender Singh Saggu 2
Ashish Kumar Sharma 1
Anil Sharma 1
Rakesh Kumar Jat 1
1 Department of Pharmaceutics, Gyan Vihar School of Pharmacy, SGVU, Jaipur, India
2 Department of Pharmaceutical Chemistry, Lordshiva College of Pharmacy, Sirsa, Haryana, India
Abstract
Background : Nebivolol hydrochloride is a third generation β-blocker with highly selective β1 -receptor antagonist with antihypertensive properties having plasma half life of 10 h and 12% oral bioavailability. The aim of the present investigation was to form matrix type transdermal patches containing Nebivolol hydrochloride to avoid its extensive hepatic first pass metabolism, lesser side effect and increase bioavailability of drug.
Materials and Methods: Matrix type transdermal patches containing Nebivolol hydrochloride were prepared using EudragitRS100, HPMC K100M (2:8) polymers by solvent evaporation technique. Aluminum foil was used as a backing membrane. Polyethylene glycol (PEG) 400 was used as plasticizer and Dimethyl sulfoxide (DMSO) was used as a penetration enhancer. Drug polymer interactions determined by FTIR and standard calibration curve of Nebivolol hydrochloride were determined by using UV estimation.
Result : The systems were evaluated physicochemical parameters and drug present in the patches was determined by scanning electron microscopy. All prepared formulations indicated good physical stability. In vitro drug permeation studies of formulations were performed by using Franz diffusion cells using abdomen skin of Wistar albino rat. Result showed best in vitro skin permeation through rat skin as compared to all other formulations prepared with hydrophilic polymer containing permeation enhancer.
Conclusions: It was observed that the formulation containing HPMC: EudragitRS100 (8:2) showed ideal higuchi release kinetics. On the basis of in vitro drug release through skin permeation performance, Formulation F1 was found to be better than other formulations and it was selected as the optimized formulation.

Keywords

1. Chien YW. Novel drug delivery systems: Transdermal Therapeutic Systems. New York: Marcel Dekker, Inc., 1982. p. 523-52.  Back to cited text no. 1
    
2. Costa P, Ferreria DC, Morgado R, Sousa Lobo JM. Design and evaluation of alorazepam transdermal delivery system. Drug Dev Ind Pharm 1997;23:939-44.  Back to cited text no. 2
    
3. Morrow T. Transdermal patches are more than skin deep. Manag care [serial online] 2004;13:50-1. Available from: http://www.managedcaremag.com/archives/0404/0404.biotech.html [Last cited on 2011 Feb 04].  Back to cited text no. 3
    
4. Bhowmik D, Chiranjib, Chandira M, Jayakar B, Sampath KP. Recent advances in transdermal drug delivery system. Int J Pharm Tech Res 2010;2:68-77.  Back to cited text no. 4
    
5. Jatav VS, Saggu JS, Jat RK, Sharma AK, Singh RP. Recent advances in development of transdermal patches. Pharmacophore (An International Research Journal) 2011;2:287-97.  Back to cited text no. 5
    
6. Veverka A, Salinas JL. Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag 2007;3:647-54.  Back to cited text no. 6
[PUBMED]    
7. Evangelista S, Garbin U, Pasini AF, Stranieri, C, Boccioletti V, Cominacini L. Effect of dl-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007;55:303-9.  Back to cited text no. 7
    
8. Galderisi M, D'Errico A, Sidiropulos M, Innelli P, de Divitiis O, De Simone G. Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension. J Hypertens 2009;27:2108-15.  Back to cited text no. 8
[PUBMED]    
9. Anthony CM, Osselton MD, Widdop B. Analysis of drugs and poisons 2004. Available from: http://mtnviewfarm.net/drugs-poisons-1149.html. [Last cited on 2012 Jun 25].  Back to cited text no. 9
    
10. Gupta JR, Tripathi P, Irchhiaya R, Garud N, Dubey P, Patel JR. Formulation and evaluation of matrix type transdermal patches of Glibenclamide. Int J Pharm Sci Drug Res 2009;1:46-50.  Back to cited text no. 10
    
11. Patel HJ, Patel JS, Patel KD. Transdermal Patch for Ketotifen Fumarate (KTF) as Asthmatic Drug. Int J Pharm Tech Res 2009;1:1297-304.  Back to cited text no. 11
    
12. Gannu R, Vamshi VY, Kishan V, Rao YM. Development of Nitrendipine Transdermal Patches: In vitro and Ex vivo Characterization. Curr Drug Deliv 2007;4:69-76.  Back to cited text no. 12
    
13. Sivakumar T, Selvam PR, Singh AK. Transdermal drug delivery systems for antihypertensive drugs: A review. Int J Pharm Biomed Res 2010;1:1-8.  Back to cited text no. 13
    
14. Devi VK, Saisivam S, Maria GR, Deepti PU. Design and Evaluation of Matrix Diffusion Controlled Transdermal Patches of Verapamil Hydrochloride. Drug Dev Ind Pharm 2003;29:495-503.  Back to cited text no. 14
    
15. Reddy RK, Muttalik S, Reddy S. Once daily sustained release matrix tablets of nicorandil: Formulation and in vitro evaluation. AAPS Pharm Sci Tech 2003;4:E61.  Back to cited text no. 15
    
16. Barry BW. Novel mechanism and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14.  Back to cited text no. 16
[PUBMED]    
17. Wade Hull MS. Heat-enhanced transdermal drug delivery: A survey paper. J Appl Res 2002;2:1-9.  Back to cited text no. 17
    
18. Mutalik S, Udupa N. Glibenclamide transdermal patches: Physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci 2004;93:1577-94.  Back to cited text no. 18
[PUBMED]    
19. Mathews BR. Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm 1999;25:831-56.  Back to cited text no. 19
    
20. Chien YW. Controlled Drug Delivery: Fundamentals and Applications. 2 nd Ed. In: Robinson J, Lee VH, editors. New York: Marcel Dekker, Inc.; 1987. p. 39-55.  Back to cited text no. 20
    
 
Advanced Biomedical Research
Volume 2013, July
July 2013
Pages 1-6